ADVERTISEMENT
Agent Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial
Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB
Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB
MARLBOROUGH, Mass. and SAN FRANCISCO -- Boston Scientific Corporation announced positive 12-month results from the pivotal AGENT IDE clinical trial of the AGENT™ Drug-Coated Balloon (DCB).1 Primary endpoint findings from this first clinical trial in the U.S. to evaluate the safety and effectiveness of using a DCB to treat coronary in-stent restenosis (ISR) were presented in a late-breaking clinical trial session at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation.
While coronary stenting is commonly used to restore blood flow to the heart in patients with coronary artery disease, ISR – a condition in which the stented section of the artery becomes obstructed or narrowed by plaque or scar tissue – still occurs in some cases and is addressed in 10% of U.S. percutaneous coronary interventions.2,3 The AGENT DCB is a paclitaxel-coated balloon catheter designed to re-open these vessels and then transfer the therapeutic drug to the vessel wall to help prevent ISR reoccurrence.
This trial met the primary endpoint of target lesion failure4 (TLF) at 12 months with the AGENT DCB demonstrating statistical superiority to uncoated balloon angioplasty (17.9% vs. 28.7%; P=0.006). These differences were mainly driven by significantly reduced rates of myocardial infarction related to the target vessel (TV-MI, or heart attack) and the need for a target lesion revascularization (TLR, or a repeated percutaneous coronary intervention) procedure. Overall, data demonstrated an approximate 38% relative risk reduction in TLF, and additional 12-month event rates for the AGENT DCB vs. uncoated balloon included:
- Zero definite/probable cases of clotting within the stent, known as stent thrombosis (0.0% vs. 3.9%, P=0.001)
- 51% risk reduction in TLR (12.4% vs. 24.0%, P=0.002)
- 49% risk reduction in TV-MI (6.4% vs. 12.3%, P=0.03)
"Positive outcomes in this complex trial population – from the markedly lower rate of target lesion failure to the significant reduction in heart attack and no stent thromboses – support the AGENT DCB as an alternative treatment option for coronary in-stent restenosis," said principal investigator Dr. Robert W. Yeh, section chief of interventional cardiology at the Beth Israel Deaconess Medical Center, and the Katz-Silver Family Professor of Medicine at Harvard Medical School. "Meaningful therapy advancements for this condition are critical, and the ability to reduce the risk of restenosis without using radiation or introducing another layer of metal stenting is a promising step forward."
The data presented today from this multicenter, prospective and randomized controlled AGENT IDE trial include the first 480 of 600 patients enrolled across 40 U.S. sites.5 Within the patient population, 44% had multiple stent layers in the target lesion, and 51% were diabetic.
"These encouraging results add to the growing body of clinical evidence supporting the AGENT DCB, spanning nearly 7,400 patients in 14 completed and ongoing studies worldwide," said Janarthanan Sathananthan, MD, chief medical officer, Interventional Cardiology Therapies, Boston Scientific. "In light of the successful real-world use of the device outside the U.S., we look forward to using these encouraging data to support FDA approval and bringing this important therapy to more physicians and patients in need."
The AGENT DCB was approved in Japan in 2023 and received CE Mark in 2014 for the treatment of patients with ISR and previously untreated small vessel coronary disease. Used to treat more than 100,000 patients globally to date, this technology was granted Breakthrough Device designation by the U.S. Food and Drug Administration in 2021, a status intended to provide patients more timely access to novel devices that may provide a substantial improvement over existing therapies. More information on the AGENT IDE trial is available here.
The AGENT DCB is an investigational device. Restricted by Federal law to investigational use only. Not available for sale in the U.S.
* Dr. Robert Yeh is a paid consultant of Boston Scientific Corporation. He has not been compensated in connection with this press release.
1 Yeh RW, Bachinsky W, Stoler R, et al. Rationale and design of a randomized study comparing the AGENT drug coated balloon to plain old balloon angioplasty in patients with In-stent restenosis. American Heart Journal. 2021;241:101-107. doi:10.1016/j.ahj.2021.07.008.
2 Moussa ID, Mohananey D, Saucedo J, et al. Trends and outcomes of restenosis after coronary stent implantation in the United States. J Am Coll Cardiol. 2020;76:1521-1531.
3 Shlofmitz E, Iantorno M, Waksman R. Restenosis of Drug-Eluting Stents: A New Classification System Based on Disease Mechanism to Guide Treatment and State-of-the-Art Review. Circ Cardiovasc Interv. 2019 Aug;12(8):e007023. doi: 10.1161/CIRCINTERVENTIONS.118.007023.
4 TLF was defined as myocardial infarction relative to the target vessel, the need for a target lesion revascularization (TLR) procedure or cardiac mortality.
5 Prespecified interim analysis of 480 patients
Find More:
The Latest Clinical & Industry News
Grand Rounds With Morton Kern, MD
Podcasts: Cath Lab Conversations
Go to Cath Lab Digest's current issue page
